Cohn & Wolfe wins Roche drug for heart problems

Pharmaceutical giant Roche has appointed Cohn & Wolfe to handle PR

for a drug to tackle heart problems.

The agency has won two separate pitches, gaining the worldwide account,

excluding North America, and also the UK account, to promote


The newly-created UK account was awarded following a three-way


Account director Shairoe Ebrahim leads a three-strong team and reports

to Roche PR executive Susie Hackett.

The international account was won following a two-way pitch against

Countrywide Porter Novelli.

C&W director Fiona McMillan leads a five-strong team from the agency's

London base and reports to international communication manager, Annette

Walz, who is based in Basel, Switzerland.

Medical Action Communications previously handled the account but Yunus

Jaleel, Roche international business leader, said the decision to

appoint C&W made sense due to its global reach.

He said: 'MAC did a great job, but we needed a bigger push, which is

something that Cohn & Wolfe can provide.'

The account wins make C&W the global agency for Carvedilol, as its New

York office has handled the US PR effort for the last three years.

In the US, the drug is produced by GlaxoSmithKline and called Coreg.

In the UK, it is known as Eucardic and across the Continent, it is known

as Dilatrend.

The treatment is a beta-blocking agent used to treat heart failure,

hypertension and angina.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in